These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 15285707)
1. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Franchini G; Gurunathan S; Baglyos L; Plotkin S; Tartaglia J Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S75-88. PubMed ID: 15285707 [TBL] [Abstract][Full Text] [Related]
2. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M J Virol; 2017 May; 91(9):. PubMed ID: 28179536 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models. Chea LS; Amara RR Expert Rev Vaccines; 2017 Oct; 16(10):973-985. PubMed ID: 28838267 [TBL] [Abstract][Full Text] [Related]
4. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview. Girard M; Habel A; Chanel C C R Acad Sci III; 1999 Nov; 322(11):959-66. PubMed ID: 10646090 [TBL] [Abstract][Full Text] [Related]
5. Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways. Gómez CE; Perdiguero B; Sánchez-Corzo C; Sorzano COS; Esteban M Viruses; 2017 Dec; 10(1):. PubMed ID: 29280955 [TBL] [Abstract][Full Text] [Related]
7. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302 [TBL] [Abstract][Full Text] [Related]
8. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219 [TBL] [Abstract][Full Text] [Related]
9. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828 [TBL] [Abstract][Full Text] [Related]
15. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Esteban M Hum Vaccin; 2009 Dec; 5(12):867-71. PubMed ID: 19786840 [TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200 [TBL] [Abstract][Full Text] [Related]
17. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Paris RM; Kim JH; Robb ML; Michael NL Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348 [TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions. Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G Viral Immunol; 1999; 12(4):281-96. PubMed ID: 10630788 [TBL] [Abstract][Full Text] [Related]